ARV overview and toxicity Dr Francois Venter Reproductive Health Research Unit University of the Witwatersrand.

Slides:



Advertisements
Similar presentations
1 AIDS EPIDEMIC IN COTE DIVOIRE TCHOMIAN Clement ADJE Technical Advisor, for care and support EGPAF.
Advertisements

Hopital Pitié Salpérière
HIV in Brazil Ana Paula Pfitscher Cavalheiro
Management of ART in Albania : From the European Guidelines to the real practice. Arjan Harxhi MD, MSc, PhD University Hospital Center of Tirana Mother.
Key1 ARV Treatment Guidelines for a Public Health Approach Product Selection for HIV Treatment Vincent Habiyambere January 2006.
ART in HIV-Infected Patients with TB: Research Priorities Group II Facilitator: David Cohn Rapporteur: Soumya Swaminathan.
Rational Drug Use Supported by USAID Prescribing, Dispensing, Counseling and Adherence in ART Programs.
ARV Nurse Training, Africaid, 2004 ARV Nurse Training Programme Marcus McGilvray & Nicola Willis Antiretrovirals in Children.
ARV failure and resistance for the paediatrician
WHO Guidelines and future perspectives for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization.
Kuala Lumpur, July 2nd 2013 The ANRS International VISCONTI Post Treatment Controller Cohort.
CD4 and VL Monitoring: Research and Development needs and Policy implications Monitoring ART session XVIII IAC Vienna 2010 Prof Charles Gilks UNAIDS India.
Treatment as Prevention (TasP)
Switching HIV Regimens – When, Why, and to What Pedro Cahn, MD Frank Palella, MD Graeme Moyle, MD Calvin Cohen, MD.
Drug Treatment Regimens: How and why WHO makes its global recommendations Prof Charles Gilks Director, Co-ordinator Antiretroviral Treatment and Care Department.
M ANAGING ARV REGIMEN FAILURE IN THE HIV INFECTED CHILD Dr L Keet Centre of Excellence HIV Directorate.
April 15 Understanding HIV Treatment and adherence. The African Eye Trust HIV Treatment Information Event By Badru Male&Elijah Amooti.
A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.
High rates of survival, virologic suppression and immune reconstitution among patients receiving second-line ART in the Indian national programme B.B.
The new guidelines Dr Francois Venter Reproductive Health and HIV Research Unit University of the Witwatersrand Feb 2010.
KITSO AIDS Training Program
Changing Therapy Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents published October 2006 AETC NRC Slide Set.
HIV AND HIV MUTANTS E. Chigidi and E. Lungu University of Botswana Private Bag 0022 Gaborone, Botswana.
ANTIRETROVIRAL THERAPY Dr. Samuel Mwaniki (BPharm., MSc TID, UoN) University of Nairobi ISO 9001: Certified
Accomplishments Year 1 Encouraged HIV testing counseling with referrals to Phidisa 1 Education of Nursing Staff on Pediatric Wards Lectures to Medical.
WHO Guidelines for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization.
Salvage Antiretroviral Therapy Guiding Principles, Strategies and the Role of Resistance Testing.
David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.
Introduction to ARV therapy
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
THE NEVEREST STUDY AT RAHIMA MOOSA MCH Ashraf Coovadia Adjunct Professor Enhancing Childhood HIV Outcomes (Wits Paediatric HIV Clinics) Rahima Moosa Mother.
Global HIV Resistance: The Implications of Transmission
Nurses SOAR! Training Curricula Series For More Information and Inquiries:
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.
UK-CAB Jan05 BHIVA treatment guidelines UK-CAB - 28 Jan 2005 Simon Collins, HIV i-Base.
WHO - PSM 14/7/2005 Principles for selection of medicines Dr Mary R. Couper Quality Assurance and Safety of Medicines WHO.
Guidelines for the use of antiretroviral agents in HIV infections in Taiwan, revised in 2002 by Infectious Diseases Society of the ROC and Taiwan AIDS.
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
HIV i-Base: Training for Advocates, 10/2004www.i-Base.info Section 3: Introduction to ARV Therapy HIV i-Base STEP EATG HIV Training for Advocates.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Update on HIV Therapy Elly T Katabira, FRCP Department of Medicine Makerere University Medical School Scaling up Treatment Programs: Issues, Challenges.
ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.
Long Term Therapeutic Success of Etravirine in Switch and Naive Patients L.Bull, M.Bower, M.Nelson Chelsea and Westminster Hospital, London.
An update on HIV prevention and treatment Prof Francois Venter Wits Reproductive Health and HIV Institute (WRHI) University of the Witwatersrand Oct 2012.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Treatment-Experienced Patients in Resource- Limited Settings Susan M. Graham Assistant Professor, Medicine.
1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Cost-effectiveness of initiating and monitoring HAART based on WHO versus US DHHS guidelines in the developing world Peter Mazonson, MD, MBA Arthi Vijayaraghavan,
Virology – Antivirals 2 JU- 2 nd Year Medical Students By Dr Hamed AlZoubi – Microbiology and Immunology Department – Mutah University. MBBS (J.U.S.T)
First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.
PRESENTED AT THE 9TH IAS CONFERENCE ON HIV SCIENCE - PARIS, FRANCE
Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;
ARV-trial.com Switch to LPV/r + RAL KITE Study 1.
Providing ARVs to children in resource limited settings
Cross-sectional assessment of patient outcomes using a systematic file review process: Results from 12,987 patient files Ambereen Jaffer, Gesine Meyer-Rath,
What’s New in the Perinatal Guidelines
EVALUATION OF ANTIRETROVIRAL THERAPY FOLLOWED BY AN EDUCATIONAL INTERVENTION TO INCREASE APPROPRIATE USE IN ZIMBABWE.
St Stephen’s Centre, Chelsea & Westminster Hospital, United Kingdom
HIV Treatment: What Can You Do to Get and Keep Patients in Care?
Our Strategies for Viral Load Suppression
HIV Update 2018: A Front Row Seat
Comparison of NNRTI vs PI/r
Switch to LPV/r monotherapy
Switch to LPV/r monotherapy
EAC for children.
Characterizing Virological Suppression in Today's Treatment Paradigm
ANTIRETROVIRAL RESISTANCE IN CLINICAL PRACTICE
INTRODUCTION OBJECTIVES METHODS RESULTS DISCUSSION
Presentation transcript:

ARV overview and toxicity Dr Francois Venter Reproductive Health Research Unit University of the Witwatersrand

HAART experience Current HAART experience Future safety and efficacy < 9 years

ddI d4T AZT 3TC 2 Nukes Non-nuke Efavirenz/ nevirapine Protease Kaletra Failure – VL>5000

Guidelines….Americans ► All symptomatic patients (CD4/VL not an issue) ► For chronic infection: - CD4<500 or - CD4<500 or - viral load> – viral load> –

So when to start? Critical questions… ► Can HIV be eradicated with HAART? ► Better virological outcomes with earlier treatment? ► Better immunological responses with earlier treatment? ► Lower drug toxicity with earlier treatment? ► Are there better clinical outcomes?

So when to start? Critical questions… ► Can HIV be eradicated with HAART? NO ► Better virological outcomes with earlier treatment? ► Better immunological responses with earlier treatment? ► Lower drug toxicity with earlier treatment? ► Are there better clinical outcomes?

So when to start? Critical questions… ► Can HIV be eradicated with HAART? NO ► Better virological outcomes with earlier treatment? ► Better immunological responses with earlier treatment? ► Lower drug toxicity with earlier treatment? ► Are there better clinical outcomes?

So, to get maximum viral suppression… ► Viral load not an issue ► CD4<200 not ideal, but not bad ► CD4<50 definitely less effective ► CD and above 350 – get equivalent responses

So when to start? Critical questions… ► Can HIV be eradicated with HAART? NO ► Better virological outcomes with earlier treatment? NO ► Better immunological responses with earlier treatment? ► Lower drug toxicity with earlier treatment? ► Are there better clinical outcomes?

So when to start? Critical questions… ► Can HIV be eradicated with HAART? NO ► Better virological outcomes with earlier treatment? NO ► Better immunological responses with earlier treatment? ► Lower drug toxicity with earlier treatment? ► Are there better clinical outcomes?

Immunological outcomes… ► Need quantitative and qualitative outcome ► CD4 is rough but robust marker ► The lower the CD4, the less recovery occurs

Immunology cont… ► AIDS 2001; 15;983 ICONA trial: ► CD4 rise 280 if started >350, ► CD4 rise 281 if CD , and ► CD4 rise 186 if<200 ► Almost no difference in VL undetectable

Immunology cont… ► Ann Intern Med 2000;133:401 – 17% patients only had virological response

Immunology cont… ► But: even with no CD4 response - significant benefit (Lancet 1999;353:863 – 20.1% vs 55% OI rate if no HAART)

Immunology cont… ► Ideal: initiate before critical CD4 reached

So when to start? Critical questions… ► Can HIV be eradicated with HAART? NO ► Better virological outcomes with earlier treatment? NO ► Better immunological responses with earlier treatment? YES ► Lower drug toxicity with earlier treatment? ► Are there better clinical outcomes?

So when to start? Critical questions… ► Can HIV be eradicated with HAART? NO ► Better virological outcomes with earlier treatment? NO ► Better immunological responses with earlier treatment? YES ► Lower drug toxicity with earlier treatment? ► Are there better clinical outcomes?

Drug toxicity… ► In general – the lower the CD4, the higher the incidence of short-term toxicity ► BUT – the long-term toxicity is the most worrying: lipodystrophy a major reason for change in guidelines; lactic acidosis emerging as problem ► Delay=more short term toxicity, but delays onset of long term toxicity

So when to start? Critical questions… ► Can HIV be eradicated with HAART? NO ► Better virological outcomes with earlier treatment? NO ► Better immunological responses with earlier treatment? YES ► Lower drug toxicity with earlier treatment? Short term YES, long term NO ► Are there better clinical outcomes?

So when to start? Critical questions… ► Can HIV be eradicated with HAART? NO ► Better virological outcomes with earlier treatment? NO ► Better immunological responses with earlier treatment? YES ► Lower drug toxicity with earlier treatment? YES and NO ► Are there better clinical outcomes with earlier treatment?

BUT….. ► All retrospective data ► Some discordance from the data ► Blacks and women under-represented ► ?role age, women ► What happens at 3,5, 10 years? ► None of it from Africa ► Does starting later increase risk of TB? When all think alike, no one is thinking - Lippman

Side effects Dr Francois Venter Reproductive Health Research Unit

Johannesburg Hospital ► 1 st 350 patients: 1 st 10 weeks ► 44% significant side effects ► Dizziness, confusion, rash, bad dreams, peripheral neuropathy, anaemia ► 10 stopped! Rash, peripheral neuropathy, dizziness ► IRIS is a problem - ?side effects…

Teratogenicity ► “Safe” vs “unknown” ► C vs B: ► For SA: nevirapine vs efavirenz – we’ll find out fast ► Do NOT confuse teratogenicity with maternal toxicity (lactic acidosis)

Non Nucleoside RTI’s ► Nevirapine and Efavirenz - Rash ► Common - up to 20% ► Stevens Johnson Syndrome - Liver Toxicity : up to 20% of pts on NVP, 2x higher in females, can be fatal. LFTs must be done - Rash - Neuropsychiatric

GIT ► All manner ► Pancreatitis – all the d’s

MARROW SUPPRESSION ► All NRTI’s  Most common with AZT  Effect of uncontrolled HIV  Other causes e.g. infections, nutritional, autoimmune, drugs and infiltrations Investigations: Full Blood count & smear Reticulocyte count, coombs Vitamin B12, Red cell folate, Iron studies Bone marrow aspirate, trephine and TB culture

NEUROPATHY  Predominantly axonal degeneration  EMG  Exclude ► Drugs (INH, Metronidazole, Dapsone) ► Alcohol, Diabetes, Hypothyroidism ► B12 deficiency  Treatment : 1. Stop drugs; 2. Rx underlying pathology; 3. Avoid trauma; 4. Analgesia ►

Lactic Acidosis ► d4T, all the others ► Clinical Symptoms and Signs Loss weight Nausea, Vomiting Abdominal discomfort Extreme Fatigue Hyperventilation Liver failure and Pancreatitis

MYOPATHY  ?  Mostly AZT  Proximal myopathy

Protease Inhibitors ► Lipodystrophy  Fat redistribution  Raised triglycerides and cholesterol  Elevated blood sugar ► General symptoms are moderately severe and relatively common ► Nephrolithiasis (Indinavir >30%)

Common side effects and HAART… ► Diabetes ► Hypertension ► Raised cholesterol, decreased HDL, raised LDL ► Endothelial dysfunction ► Lipodystrophy, with increased intra- abdominal fat

Prescription pad Dr WDF Venter, Physician 27 Eton Road, Parktown, 2193 (011) October 2005 Re: Mr John Smit Discovery Super-duper Vitality Xtra member Please provide: 1) Trizovir 1 BD 2) Atenolol 100 mg/d 3) Aspirin 150mg/d 4) Perindopril 4 mg/d 5) Pravastatin 1/d Regards WDF Venter FCP (SA), DTM&H 6) Metformin 850mg/d 7) Glicazide 80mg BD 8) Bezalip 1 BD 9) Prozac 20mg/d 10) Viagra 25mg PRN

Abdominal MRI Scans Control SubjectIncreased VAT SAT

What Are the Treatment Options? ► Lifestyle changes  Exercise  Diet ► Lipid-lowering agents  Fibric acid derivatives  Statins ► Drugs  Growth hormone  Anabolic steroids  Dietary supplements ► Hypoglycemic agents  Thiazolidinediones  Metformin ► Surgical interventions  Surgical removal/liposuction  Facial implants  Fat transfer techniques

“The drugs are toxic. The disease is toxicer.” – Dr Francesca Conradie

The END…

Drug interactions

WHAT IS THE PATIENT TAKING ? ► Prescription ? ► Non-prescription ? - OTC drugs antacids, analgesics, H2-antagonists - Alternative medicines eg St John’s Wort - Illicit drugs

ANTI-INFECTIVES - Antiretrovirals: AZT & d4T, ddI & IDV, ddC & 3TC. - Antibiotics: Clarithromycin & PIs & NNRTIs, Ciprofloxacin and ddI Rifampicin & Pis and NNRTIs also ddI, AZT Rifampicin & Pis and NNRTIs also ddI, AZT - Antifungals: Fluconazole & AZT, Ketoconazole/Itraconazole & PIs and NNRTIs also ddI

ANTICONVULSANTS - carbamazepine, phenytoin, phenobarbitone AVOID ALL PI’s and NNRTIs - Valproate AVOID AZT AND RTV

COLDS AND ALLERGY AGENTS Eg Preparations containing astemizol, loratidine, promethazine and terfenadine. AVOID WHEN ON Pis and NNRTIS

GASTROINTESTINAL AGENTS - Antacids, H2-antagonists, proton pump inhibitors Must be given 1-2 hours after ddI, IDV

CARDIOVASCULAR AGENTS - Lipitor/Zocor: AVOID Pis or change to Pravastatin - Ca antagonists: AVOID Pis - Warfarin: AVOID Pis and NNRTIs

HYPOGLYCAEMICS - Sulphonylureas - Metformin AVOID RITONAVIR

HOMEOPATHIC St John’s Wort Garlic Pills Grapefruit juice